Spyre Therapeutics (SYRE) Assets (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Assets came in at $764.0 million in Q1 2026, up 34.08% YoY from $569.8 million in Q1 2025, and down 1.78% on a QoQ basis from $777.8 million in Q4 2025.
Spyre Therapeutics (SYRE) Assets (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Assets data on file, last reported at $764.0 million in Q1 2026.
- Quarterly Assets rose 34.08% year-over-year to $764.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $764.0 million (up 34.08% YoY) and the FY2025 annual result came in at $777.8 million, up 27.82% from the prior year.
- Assets declined to $764.0 million in Q1 2026, from $777.8 million in the prior quarter.
- In the past five years, Assets ranged from a high of $777.8 million in Q4 2025 to a low of $52.5 million in Q1 2023.
- A 5-year average of $370.9 million and a median of $421.1 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets plunged 49.17% — and 2024, when it surged 829.6%.
- Tracing SYRE's Assets over 5 years: stood at $71.1 million in 2022, then surged by 380.52% to $341.9 million in 2023, then surged by 77.99% to $608.5 million in 2024, then advanced by 27.82% to $777.8 million in 2025, then retreated by 1.78% to $764.0 million in 2026.
- The last three Assets figures came in at $764.0 million (Q1 2026), $777.8 million (Q4 2025), and $504.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.17 Bn |
| Mar 31, 2026 | 763.95 Mn |
| Dec 31, 2025 | 777.78 Mn |
| Sep 30, 2025 | 504.60 Mn |
| Jun 30, 2025 | 538.83 Mn |
| Mar 31, 2025 | 569.78 Mn |
| Dec 31, 2024 | 608.48 Mn |
| Sep 30, 2024 | 421.09 Mn |
| Jun 30, 2024 | 436.07 Mn |
| Mar 31, 2024 | 487.60 Mn |
| Dec 31, 2023 | 341.86 Mn |
| Sep 30, 2023 | 207.27 Mn |
| Jun 30, 2023 | 243.53 Mn |
| Mar 31, 2023 | 52.45 Mn |
| Dec 31, 2022 | 71.14 Mn |
| Sep 30, 2022 | 91.57 Mn |
| Jun 30, 2022 | 106.71 Mn |
| Mar 31, 2022 | 83.17 Mn |
| Dec 31, 2021 | 109.93 Mn |
| Sep 30, 2021 | 129.06 Mn |